RON HOOGEVEEN to Risk
This is a "connection" page, showing publications RON HOOGEVEEN has written about Risk.
Connection Strength
0.145
-
Role of lipid and lipoprotein profiles in risk assessment and therapy. Am Heart J. 2003 Aug; 146(2):227-33.
Score: 0.047
-
A prospective study of soluble receptor for advanced glycation end products and adipokines in association with pancreatic cancer in postmenopausal women. Cancer Med. 2018 05; 7(5):2180-2191.
Score: 0.032
-
Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis. 2014 Jan; 232(1):86-93.
Score: 0.024
-
Racial differences in association of elevated interleukin-18 levels with type 2 diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care. 2012 Jul; 35(7):1513-8.
Score: 0.021
-
Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012 Jan 17; 125(2):241-9.
Score: 0.021